On December 21, 2018 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, Iovance Biotherapeutics, DEC 21, 2018, View Source;p=irol-newsArticle&ID=2381465 [SID1234532223]). Details of the presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenter: Maria Fardis, Ph.D., President and Chief Executive Officer
Date: Thursday, Jan. 10, 2019
Time: 10:30 a.m. PST
Webcast: A live and archived audio webcast of the presentation will be available in the "Investors" section at www.iovance.com.